BiotechTube

KPI-121 1% + Prednisolone acetate

Phase 3Terminated
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ocular Inflammation

Conditions

Ocular Inflammation

Trial Timeline

Jul 3, 2018 → Oct 18, 2018

NCT ID
NCT03596723

About KPI-121 1% + Prednisolone acetate

KPI-121 1% + Prednisolone acetate is a phase 3 stage product being developed by Kala Pharmaceuticals for Ocular Inflammation. The current trial status is terminated. This product is registered under clinical trial identifier NCT03596723. Target conditions include Ocular Inflammation.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03596723Phase 3Terminated

Competing Products

20 competing products in Ocular Inflammation

See all competitors
ProductCompanyStageHype Score
lotilaner + VehicleTarsus PharmaceuticalsPhase 2
47
Mirabegron + PlaceboAstellas PharmaPhase 1
33
ISV-303 + ISV-303 + DuraSite Vehicle + Xibrom™Sun PharmaceuticalPhase 1/2
41
ISV-303Sun PharmaceuticalPhase 3
77
ISV-303Sun PharmaceuticalPhase 3
77
ONO-9054 + LatanoprostOno PharmaceuticalPhase 2
52
ONO-9054 + PlaceboOno PharmaceuticalPhase 1
33
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Santen PharmaceuticalPhase 3
77
Tafluprost, timolol maleateSanten PharmaceuticalPre-clinical
23
DE-111 ophthalmic solutionSanten PharmaceuticalPhase 3
77
DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
77
STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
77
DE-117 + Latanoprost ophthalmic solutionSanten PharmaceuticalPhase 3
77
DE-117 ophthalmic solution + Timolol ophthalmic solutionSanten PharmaceuticalPhase 3
77
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
77
Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + PlaceboAbbViePhase 2
52
AZD4017 + Placebo + AZD4017 + PlaceboAstraZenecaPhase 2
52
dorzolamide hydrochloride (+) timolol maleateMerckApproved
85
INS115644 Ophthalmic Solution + Placebo + INS115644 Ophthalmic Solution + INS115644 Ophthalmic Solution + INS115644 Ophthalmic SolutionMerckPhase 1
33
SAD448NovartisPhase 1
33

Other Products from Kala Pharmaceuticals

loteprednol etabonate 0.25% ophthalmic suspensionApproved
77
KPI-121 1% Ophthalmic Suspension dosed BID + Vehicle of KPI-121 Ophthalmic Suspension dosed BIDPhase 3
69
KPI-121 Ophthalmic Suspension + VehiclePhase 3
69
KPI-121 0.25% Ophthalmic Suspension + Vehicle of KPI-121 0.25% Ophthalmic SuspensionPhase 3
69
KPI-121 0.25% + KPI-121 1.0% + Vehicle of KPI-121 0.25% + Vehicle of KPI-121 1.0%Phase 3
69